CC3 COST-EFFECTIVENESS ANALYSIS OF VORETIGENE NEPARVOVEC VERSUS BEST SUPPORTIVE CARE IN PATIENTS WITH RPE65-MEDIATED INHERITED RETINAL DYSTROPHY: A FRENCH HEALTHCARE SYSTEM PERSPECTIVE
Abstract
Authors
C. Cariou J. Baba A. Gherardi S. Roze D. Viriato